Stock Taper
SCREENER COMPARE ANY 2 STOCKS
SVRA
SAVARA INC.
NASDAQ
$5.26
▼ DOWN 4.19% (-0.23)

KEY STATISTICS

Market Cap$1.08 B
52w High$7.00
52w Low$3.21
Dividend Yield—
Frequency—
P/E-9.39
Volume1.33M
Shares Out.204.93M

COMPANY

LEADERSHIP

Matthew Pauls
CHIEF EXECUTIVE
Matthew Pauls

COMPENSATION 2026

Salary$660,000
Stock Awards$3,870,000
Incentive Plan Pay$297,000
All Other Comp.$18,000
Total$4,845,000

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 28, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
70

PRICE TARGET

Target High$10.00
Target Low$10.00
Target Median$10.00
Target Consensus$10.00

UPCOMING EARNINGS

DateNov 11, 2026
DayWednesday
Rev. Est.$500.00K
NOV
11
WED

SPLIT RECORD

DATETYPERATIO
2017-04-28Reverse1:70
2010-04-26Reverse1:25
2002-06-11Reverse251:500

PRICE

$5.26 ▼ DOWN 4.19% (−$0.23)
OVERLAYS
$5.25$5.33$5.40$5.489:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM5.26

About Savara Inc.

https://www.savarapharma.com ↗

Savara Inc. is a Texas-based clinical-stage biopharmaceutical company developing molgramostim, an inhaled therapy in Phase III for rare respiratory disease autoimmune pulmonary alveolar proteinosis.

INDUSTRY

Biotechnology

A PRODUCT SAVARA INC. IS KNOWN FOR

MOLBREEVI (molgramostim inhalation solution)
MOLBREEVI (molgramostim inhalation solution)

MOLBREEVI is an investigational inhaled therapy in Phase 3 for autoimmune pulmonary alveolar proteinosis, a rare lung disease, with an FDA-accepted BLA, aiming to be the first approved pharmacological treatment.

COMPETITORS

COMPETITOR
ARWR COMPARE
GILD COMPARE
INSM COMPARE
VRTX COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
107
LISTED HERE
21
RANKED BY POSITION SIZE
VTI
0.00% · 6.2M
XSU.TO
0.03% · 4.0M
XBI
0.16% · 3.4M
LFSC
2.79% · 673.0K
SCHA
0.02% · 661.3K
JSML
0.61% · 411.8K
FESM
0.03% · 396.4K
XRS2.F
0.03% · 140.0K
LABU
0.11% · 123.9K
PRFZ
0.02% · 105.5K
GSSC
0.04% · 83.7K
RSSL
0.03% · 72.8K
BBC
0.62% · 59.6K
DFAS
0.00% · 23.8K
TILT
0.00% · 19.1K
RFLR
0.06% · 11.2K
BIB
0.04% · 7.3K
VETS
0.05% · 2.9K
AVSC
0.00% · 1.7K
USFMDN.MX
0.00% · 435
RESM
0.02% · 209

INSTITUTIONAL OWNERSHIP

SHARES OWNED
72.02%
HOLDERS
229
TOP 12 OF 229 · RANKED BY POSITION SIZE
Nea Management Company, LLC
24.5M sh · $133.61M
Bain Capital Life Sciences Investors, LLC
17.6M sh · $96.1M
Vr Adviser, LLC
13.7M sh · $75.02M
Deerfield Management Company, L.P. (Series C)
13.6M sh · $74.09M
Tcg Crossover Management, LLC
12.4M sh · $67.5M
Frazier Life Sciences Management, L.P.
11.5M sh · $40.92M
Blackrock, Inc.
11.3M sh · $61.65M
Vanguard Group Inc
10.0M sh · $60.55M
Polar Capital Holdings Plc
9.5M sh · $52.1M
Nantahala Capital Management, LLC
8.8M sh · $31.33M
Blackrock Inc.
8.0M sh · $32.36M
State Street Corp
6.7M sh · $36.62M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity3
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: CHIEF FIN. & OPERATING OFFICER
Lutz Robert Matthew
Purchase · 35.0K shares
2026-07-15
★
OFFICER: CHIEF FIN. & OPERATING OFFICER
Lutz Robert Matthew
Purchase · 70.0K shares
2026-07-15
★
OFFICER: CHIEF FINANCIAL OFFICER
Lowrance David L
Purchase · 218.8K shares
2026-06-22
★
OFFICER: CHIEF FINANCIAL OFFICER
Lowrance David L
Sale · 53.4K shares
2026-06-22

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
MARKET OUTPERFORM 2
OVERWEIGHT 1
OUTPERFORM 1
6 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY Wells Fargo OVERWEIGHT Oppenheimer OUTPERFORM Citizens MARKET OUTPERFORM JMP Securities MARKET OUTPERFORM Guggenheim BUY

SECTORS PEERS

PEERPRICE
TNGX$23.34COMPARE
NBTX$41.23COMPARE
GHRS$27.94COMPARE
BCAX$23.43COMPARE
TYRA$24.94COMPARE
KURA$12.66COMPARE
GERN$1.51COMPARE
RZLT$4.62COMPARE